ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines.
Company Details
- Employees
- 7
- Founded
- 2021
- Address
- New York, Ny, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.projenx.com
- Keywords
- Neuroscience, Motor Neurons, Neurology.
- HQ
- New York, NY
Projenx Questions
Projenx's website is http://www.projenx.com
Projenx's LinkedIn profile is https://www.linkedin.com/company/projenx-inc
Projenx has
7 employees.
View email and phone details for 7
employees at Projenx.
Projenx's industry is
Biotechnology Research
Projenx's top competitors are
Aspen Neuroscience, Inc.,
Neurosense Therapeutics,
Eikonizo Therapeutics,
Project Als,
Leal Therapeutics,
Gc Therapeutics,
Nobias Therapeutics,
Unlearn.ai,
Avilar Therapeutics,
Quralis.
Projenx's categories are Biotechnology Research
Projenx's founding year is 2021
